Ineos Styrolution reported strong quarterly performance across the board. The specialties business revenue also witnessed traction

Glenmark Pharmaceuticals launches its first inhaled respiratory product in Europe. The company has marketing and distribution right for the product in Europe.

Overall volumes in futures & options currently stand at 1.21 crore contracts with a turnover of Rs. 11,31,488.68 crore.

Overall volumes in futures & options currently stand at 1.21 crore contracts with a turnover of Rs. 11,31,488.68 crore.

A follow-through weakness and a close below the Monday’s session low (10,774) would signal a reversal in the market. In that case, we could see correction up to the levels of 10,690-10,650. Stocks in news: DLF, Shree Pushkar Chemicals and Fertilisers, Syngene International, MCX, Wockhardt, EPC Industries, Reliance Communications, Cyient and Tata Steel.

Indian markets are likely to make a pessimistic start tracking weak global cues. The sentiments may remain dampened as the US treasury yield on the 10-year benchmark surged to its highest level since 2011, which indicates a more hawkish Federal Reserve going ahead with rate hikes and that would not go down well with the emerging markets.

The share price of pharmaceutical major Sun Pharma plunged by over 7 per cent during the previous week on the back of declining sales of its key specialty products and speculation about price erosion.  

Every investor wants his investment to outperform. The mutual fund arena is well-known for steady returns in the longer term. But it too needs some diligence and planning to achieve maximum returns.

A new fund offer (NFO) is the first time offer for subscription from newly launched fund. The new fund offers are launched to raise the capital in respect to buy the shares or securities or bonds for the fund from the market. These offerings work similarly to IPOs. 

Suven Lifesciences reported strong result with good numbers across the board. The core manufacturing business witnessed robust growth aiding better top-line growth.